An analysis of international strategies for monitoring and preventability described in medicinal product information: a study protocol
Sartori, D.; Aronson, J. K.; Noren, G. N.; Onakpoya, I. J.
Show abstract
IntroductionProduct information is intended to be a reference for healthcare professionals to verify instructions for monitoring and preventability of adverse drug reactions (ADRs), among other things. International comparisons of these documents, using the Systematic Information for Monitoring (SIM) method, have highlighted discrepancies in the instructions for monitoring, but there has been no comparison of preventability instructions. ObjectivesTo quantify and compare, across different countries, the completeness of instructions for monitoring and preventability provided to healthcare professionals in medicinal product information. MethodsWe shall retrieve information included with medicinal products that have been involved in signals communicated by regulators, in 2014-2019 and based on clinical assessments of reports of ADRs, from the websites of 35 regulatory agencies. We shall evaluate the completeness of instructions for monitoring using a modified version of the SIM method; a score of 67% will qualify a monitoring instruction as sufficiently complete. To evaluate the completeness of instructions for preventability, we have derived a framework from the Dose-responsiveness-Temporality-Susceptibility (DoTS) classification of ADRs and related implications, comprising domains and items/implications. We shall iteratively develop a threshold to define the sufficiency of completeness of instructions based on data distribution across DoTS domains. We shall present descriptive statistics by country for each item of the framework and by total scores, using tables, or figures where necessary. OutcomesOur target audience is regulators, and the results should highlight gaps in the level of information available to healthcare professionals. This study may also provide some insights into how suspicions of causality that arise from clinical assessments of reports of ADRs translate into actionable recommendations in clinical practice.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 97%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 94%
- Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies 94%
Similar papers in this journal
Similar papers in this journal
- Incidences of poor-quality pharmaceutical products in Nepal 93%
- An overview of global monitoring systems for the side effects and adverse events associated with medicinal cannabis use: A scoping review using a systematic approach 93%
- Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study) 92%
Similar papers in this journal
- Pharmacogenomics implementation training improve self-efficacy and competency to drive adoption in clinical practice 91%
- Primary Target Prediction of Bioactive Molecules from Chemical Structure 91%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.